X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs NOVARTIS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH NOVARTIS PANACEA BIOTECH/
NOVARTIS
 
P/E (TTM) x 24.4 297.0 8.2% View Chart
P/BV x 3.3 25.3 13.0% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 PANACEA BIOTECH   NOVARTIS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
NOVARTIS
Mar-17
PANACEA BIOTECH/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs149855 17.4%   
Low Rs82666 12.4%   
Sales per share (Unadj.) Rs84.1219.0 38.4%  
Earnings per share (Unadj.) Rs-18.319.1 -95.9%  
Cash flow per share (Unadj.) Rs-6.720.3 -33.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs83.7307.0 27.3%  
Shares outstanding (eoy) m61.2529.96 204.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.5 39.5%   
Avg P/E ratio x-6.339.8 -15.8%  
P/CF ratio (eoy) x-17.237.5 -46.0%  
Price / Book Value ratio x1.42.5 55.7%  
Dividend payout %052.4 0.0%   
Avg Mkt Cap Rs m7,07422,779 31.1%   
No. of employees `0002.80.7 408.0%   
Total wages/salary Rs m1,4491,393 104.0%   
Avg. sales/employee Rs Th1,874.19,736.2 19.2%   
Avg. wages/employee Rs Th527.02,066.8 25.5%   
Avg. net profit/employee Rs Th-407.7849.0 -48.0%   
INCOME DATA
Net Sales Rs m5,1546,562 78.5%  
Other income Rs m100702 14.2%   
Total revenues Rs m5,2547,264 72.3%   
Gross profit Rs m-766259 -296.0%  
Depreciation Rs m71136 1,980.5%   
Interest Rs m1,5037 20,875.0%   
Profit before tax Rs m-2,881917 -314.0%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17345 4.9%   
Profit after tax Rs m-1,121572 -196.0%  
Gross profit margin %-14.93.9 -376.9%  
Effective tax rate %-0.637.6 -1.6%   
Net profit margin %-21.88.7 -249.5%  
BALANCE SHEET DATA
Current assets Rs m3,8109,731 39.2%   
Current liabilities Rs m8,3651,830 457.0%   
Net working cap to sales %-88.4120.4 -73.4%  
Current ratio x0.55.3 8.6%  
Inventory Days Days15649 319.8%  
Debtors Days Days6725 267.2%  
Net fixed assets Rs m14,48057 25,315.0%   
Share capital Rs m61141 43.6%   
"Free" reserves Rs m9039,056 10.0%   
Net worth Rs m5,1279,196 55.8%   
Long term debt Rs m5,8320-   
Total assets Rs m19,43311,499 169.0%  
Interest coverage x-0.9128.4 -0.7%   
Debt to equity ratio x1.10-  
Sales to assets ratio x0.30.6 46.5%   
Return on assets %2.05.0 39.0%  
Return on equity %-21.96.2 -351.5%  
Return on capital %3.610.1 36.2%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,539129 1,194.1%   
Fx outflow Rs m9421,734 54.3%   
Net fx Rs m597-1,605 -37.2%   
CASH FLOW
From Operations Rs m599-380 -157.9%  
From Investments Rs m-4384,208 -10.4%  
From Financial Activity Rs m-303-3,318 9.1%  
Net Cashflow Rs m-141510 -27.7%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.6 2.0 30.0%  
FIIs % 1.3 1.6 81.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 21.5 109.8%  
Shareholders   10,259 41,647 24.6%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  FRESENIUS KABI ONCO.  FDC LTD.  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jun 18, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS